A phase 1 feasibility trial of BE-CAR33, an “off-the-shelf” base-edited CAR33 T cell therapy for acute myeloid leukemia | Science Translational Medicine
A first-in-human study demonstrates the feasibility and safety of base-edited anti-CD33 CAR T cells as a bridge to allogeneic transplantation in AML.
